{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-055181","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.696816+00:00","generated_at":"2026-05-20T03:48:38.588851+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Theriva Biologics Phase 1 data: VCN-01 well-tolerated in retinoblastoma; eye preserved in 3 of 9 patients","bullets":["VCN-01 intravitreal injection at 2E+10 vp/eye was well-tolerated; no retinal toxicity or DLTs; main AE Grade 1-2 uveitis.","Four of nine patients had improvement in vitreous seed density; 3 avoided enucleation with follow-up up to 49 months.","No Grade >=3 ocular or systemic toxicities; selective replication in tumor cells confirmed by immunohistochemistry.","RP2D defined as 2 doses of 2E+10 vp/eye; VCN-01 genomes in aqueous humor correlated with vitreous seed persistence."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-055181","json":"https://secwatch.observer/filing/0001104659-25-055181.json","markdown":"https://secwatch.observer/filing/0001104659-25-055181.md","text":"https://secwatch.observer/filing/0001104659-25-055181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925055181/0001104659-25-055181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925055181/tm2516499d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:48:38.588851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}